A platinum-based hybrid drug design approach to circumvent acquired resistance to molecular targeted tyrosine kinase inhibitors
Yuming Wei(Chinese University of Hong Kong), Kenneth K.W. To(Chinese University of Hong Kong)
Cited by 10
Related Papers
MicroRNAs in the prognosis and therapy of colorectal cancer: From bench to bedside
|World Journal of Gastroenterology|2018|205
Suppression of Hypoxia-inducible Factor 1α (HIF-1α) Transcriptional Activity by the HIF Prolyl Hydroxylase EGLN1
|Journal of Biological Chemistry|2005|113
Targeting the <scp>ABCG</scp>2‐overexpressing multidrug resistant (<scp>MDR</scp>) cancer cells by <scp>PPAR</scp>γ agonists
|British Journal of Pharmacology|2013|35
Circumvention of Gefitinib Resistance by Repurposing Flunarizine via Histone Deacetylase Inhibition
|ACS Pharmacology & Translational Science|2023|8